1
|
Groszman L, Hubermann JA, Kooner P, Alamiri N, Bozzo A, Aoude A. The Impact of Adjunct Medical Therapy on Survival after Spine Metastasis: A Systematic Review and Pooled Data Analysis. Cancers (Basel) 2024; 16:1425. [PMID: 38611103 PMCID: PMC11011004 DOI: 10.3390/cancers16071425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Revised: 03/30/2024] [Accepted: 03/31/2024] [Indexed: 04/14/2024] Open
Abstract
Targeted therapy has greatly improved the outlook for patients with spinal metastatic cancers. Scoring systems like the Tokuhashi or Tomita scores are commonly used to predict prognosis and inform surgical decisions, but they are outdated and fail to consider recent advancements. We aimed to investigate the current state of the literature and treatment options pertaining to advancements in targeted therapy compared to other forms of medical management for metastatic spinal tumors. This study represents the first comprehensive systematic review that encompasses the most common primary cancers that metastasize to the spine and evaluates the median overall survival (mOS) across five different medical treatment modalities as well as surgical intervention. Additionally, our study analyzes the tumor receptor status in conjunction with these treatments. A PubMed search was conducted, and according to the PRISMA guidelines, 28 articles out of 1834 met the inclusion criteria. The pooled data analysis highlighted the superior efficacy of targeted therapy, evidenced by a significant improvement in the mOS and lower hazard ratios in patients with lung and breast cancers who received targeted therapy compared to those who did not. Our study provides valuable insights into the recent advancements in the medical management of metastatic spinal tumors. Future indications include incorporating this literature into personalized treatment approaches for metastatic spinal tumors.
Collapse
Affiliation(s)
| | | | | | | | | | - Ahmed Aoude
- Department of Orthopaedic Surgery, McGill University Health Centre, Montreal, QC H4A 3J1, Canada; (L.G.); (J.A.H.); (N.A.)
| |
Collapse
|
2
|
Okai BK, Lipinski LJ, Ghannam MM, Fabiano AJ. Expected motor function change following decompressive surgery for spinal metastatic disease. NORTH AMERICAN SPINE SOCIETY JOURNAL 2023; 15:100240. [PMID: 37457395 PMCID: PMC10345847 DOI: 10.1016/j.xnsj.2023.100240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 06/25/2023] [Accepted: 06/27/2023] [Indexed: 07/18/2023]
Abstract
Background Motor function in patients with spinal metastatic disease (SMD) directly impacts a patient's ability to receive systemic therapy and overall survival. Spine surgeons may be in the challenging position to advise a patient on expected motor function outcomes and determine a patient's suitability as a surgical candidate. We present this study to provide this critical information on anticipated motor function change to spine surgeons. Methods Consecutive patients undergoing spinal surgery for SMD at a National Cancer Institute-designated cancer institute were prospectively enrolled. Patient motor function status before and after surgery was assessed using the standard 0 to 5 five-point muscle strength grading scale. The difference in presurgical and postsurgical motor function (proximal and distal) was used to assess motor function changes following surgery. Results A total of 171 patients were included. The mean age was 62.7±10.46 years and 40.9% (70) were female. Common primary malignancy types were lung (49), kidney (28), breast (25), and prostate (23). The average proximal and distal motor function difference was 0.38 (standard deviation=1.02, p<.0001) and 0.32 (standard deviation=0.91, p<.0001) respectively showing an improvement following surgery. Patients with proximal presurgical motor function of 2, 3, and 4 had an improved motor function in 73%, 77%, and 73% of the patients. Patients with distal presurgical motor function of 2, 3, and 4 had an improved motor function in 80%, 89%, and 70% of the patients. Conclusions Most patients undergoing surgery for SMD have a modest improvement in motor function following surgery. The degree of improvement in most instances is less than 1 point on a 0 to 5 motor function scale. This is critical knowledge for a spinal surgeon when evaluating SMD patients with significant preoperative motor function deficits. These results aid spinal surgeons in setting expectations and evaluating the need for rapid spinal decompression.
Collapse
Affiliation(s)
- Bernard K. Okai
- Department of Neuro-Oncology, Roswell Park Comprehensive Cancer Center, Elm & Carlton St, Buffalo, NY, 14263, United States
- Department of Neurosurgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, 955 Main St, Buffalo, NY, 14203, United States
| | - Lindsay J. Lipinski
- Department of Neuro-Oncology, Roswell Park Comprehensive Cancer Center, Elm & Carlton St, Buffalo, NY, 14263, United States
- Department of Neurosurgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, 955 Main St, Buffalo, NY, 14203, United States
| | - Moleca M. Ghannam
- Department of Neuro-Oncology, Roswell Park Comprehensive Cancer Center, Elm & Carlton St, Buffalo, NY, 14263, United States
- Department of Neurosurgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, 955 Main St, Buffalo, NY, 14203, United States
| | - Andrew J. Fabiano
- Department of Neuro-Oncology, Roswell Park Comprehensive Cancer Center, Elm & Carlton St, Buffalo, NY, 14263, United States
- Department of Neurosurgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, 955 Main St, Buffalo, NY, 14203, United States
| |
Collapse
|
3
|
Rabah NM, Jarmula J, Hamza O, Khan HA, Chakravarthy V, Habboub G, Wright JM, Steinmetz MP, Wright CH, Krishnaney AA. Metastatic Breast Cancer to the Spine: Incidence of Somatic Gene Alterations and Association of Targeted Therapies With Overall Survival. Neurosurgery 2023; 92:1183-1191. [PMID: 36735514 DOI: 10.1227/neu.0000000000002348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Accepted: 11/07/2022] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND The increase in use of targeted systemic therapies in cancer treatments has catalyzed the importance of identifying patient- and tumor-specific somatic mutations, especially regarding metastatic disease. Mutations found to be most prevalent in patients with metastatic breast cancer include TP53, PI3K, and CDH1. OBJECTIVE To determine the incidence of somatic mutations in patients with metastatic breast cancer to the spine (MBCS). To determine if a difference exists in overall survival (OS), progression-free survival, and progression of motor symptoms between patients who do or do not undergo targeted systemic therapy after treatment for MBCS. METHODS This is a retrospective study of patients with MBCS. Review of gene sequencing reports was conducted to calculate the prevalence of various somatic gene mutations within this population. Those patients who then underwent treatment (surgery/radiation) for their diagnosis of MBCS between 2010 and 2020 were subcategorized. The use of targeted systemic therapy in the post-treatment period was identified, and post-treatment OS, progression-free survival, and progression of motor deficits were calculated for this subpopulation. RESULTS A total of 131 patients were included in the final analysis with 56% of patients found to have a PI3K mutation. Patients who received targeted systemic therapies were found to have a significantly longer OS compared with those who did not receive targeted systemic therapies. CONCLUSION The results of this study demonstrate that there is an increased prevalence of PI3K mutations in patients with MBCS and there are a significant survival benefit and delay in progression of motor symptoms associated with using targeted systemic therapies for adjuvant treatment.
Collapse
Affiliation(s)
- Nicholas M Rabah
- Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
- Cleveland Clinic Center for Spine Health, Neurologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Jakub Jarmula
- Cleveland Clinic Center for Spine Health, Neurologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
- Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA
| | - Omar Hamza
- Cleveland Clinic Center for Spine Health, Neurologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
- Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
| | - Hammad A Khan
- Department of Neurosurgery, New York University, New York, New York, USA
| | - Vikram Chakravarthy
- Department of Neurosurgery, Memorial Sloan Kettering, New York, New York, USA
| | - Ghaith Habboub
- Cleveland Clinic Center for Spine Health, Neurologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - James M Wright
- Department of Neurosurgery, Oregon Health & Science University, Portland, Oregon, USA
| | - Michael P Steinmetz
- Cleveland Clinic Center for Spine Health, Neurologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
- Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA
| | - Christina H Wright
- Department of Neurosurgery, Oregon Health & Science University, Portland, Oregon, USA
| | - Ajit A Krishnaney
- Cleveland Clinic Center for Spine Health, Neurologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
- Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA
| |
Collapse
|
4
|
Bai J, Li Z, Guo J, Gao F, Zhou H, Zhao W, Ma X. Development of a predictive model to identify patients most likely to benefit from surgery in metastatic breast cancer. Sci Rep 2023; 13:3845. [PMID: 36890157 PMCID: PMC9995350 DOI: 10.1038/s41598-023-30793-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Accepted: 03/01/2023] [Indexed: 03/10/2023] Open
Abstract
Primary tumor resection for metastatic breast cancer (MBC) has demonstrated a survival advantage, however, not all patients with MBC benefit from surgery. The purpose of this study was to develop a predictive model to select patients with MBC who are most likely to benefit from surgery at the primary site. Data from patients with MBC were obtained from the Surveillance, Epidemiology and End Results (SEER) cohort and patients treated at the Yunnan Cancer Hospital. The patients from the SEER database were divided into surgery and non-surgery groups and a 1:1 propensity score matching (PSM) was used to balance baseline characteristics. We hypothesized that patients who underwent local resection of primary tumors had improved overall survival (OS) compared to those who did not undergo surgery. Based on the median OS time of the non-surgery group, patients from the surgery group were further categorized into beneficial and non-beneficial groups. Logistic regression analysis was performed to identify independent factors associated with improved survival in the surgery group and a nomogram was established using the most significant predictive factors. Finally, internal and external validation of the prognostic nomogram was also evaluated by concordance index (C-index) and using a calibration curve. A total of 7759 eligible patients with MBC were identified in the SEER cohort and 92 with MBC patients who underwent surgery at the Yunnan Cancer Hospital. Amongst the SEER cohort, 3199 (41.23%) patients received surgery of the primary tumor. After PSM, the OS between the surgery and non-surgery group was significantly different based on Kaplan-Meier survival analysis (46 vs. 31 months, P < 0.001), In the surgery group, 562 (55.20%) patients survived for longer than 31 months and were classified in the beneficial group. Significant differences were observed in patient characteristics between the beneficial and non-beneficial groups including age, grade, tumor size, liver metastasis, breast cancer subtype and marital status. These factors were used as independent predictors to create a nomogram. The internally and externally validated C-indices of the nomogram were 0.703 and 0.733, respectively, indicating strong consistency between the actual and predicted survival. A nomogram was developed and used to identify MBC patients who are most likely to benefit from primary tumor resection. This predictive model has the potential to improve clinical decision-making and should be considered routine clinical practice.
Collapse
Affiliation(s)
- Jinfeng Bai
- The third affiliated hospital of Kunming Medical University, Kunming, 650118, China
| | - Zeying Li
- The third affiliated hospital of Kunming Medical University, Kunming, 650118, China
| | | | - Fuxin Gao
- Kunming Medical University, Kunming, China
| | - Hui Zhou
- The third affiliated hospital of Kunming Medical University, Kunming, 650118, China
| | - Weijie Zhao
- The third affiliated hospital of Kunming Medical University, Kunming, 650118, China
| | - Xiang Ma
- The third affiliated hospital of Kunming Medical University, Kunming, 650118, China.
| |
Collapse
|
5
|
Massaad E, Bridge CP, Kiapour A, Fourman MS, Duvall JB, Connolly ID, Hadzipasic M, Shankar GM, Andriole KP, Rosenthal M, Schoenfeld AJ, Bilsky MH, Shin JH. Evaluating frailty, mortality, and complications associated with metastatic spine tumor surgery using machine learning-derived body composition analysis. J Neurosurg Spine 2022; 37:263-273. [PMID: 35213829 DOI: 10.3171/2022.1.spine211284] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Accepted: 01/05/2022] [Indexed: 01/06/2023]
Abstract
OBJECTIVE Cancer patients with spinal metastases may undergo surgery without clear assessments of prognosis, thereby impacting the optimal palliative strategy. Because the morbidity of surgery may adversely impact recovery and initiation of adjuvant therapies, evaluation of risk factors associated with mortality risk and complications is critical. Evaluation of body composition of cancer patients as a surrogate for frailty is an emerging area of study for improving preoperative risk stratification. METHODS To examine the associations of muscle characteristics and adiposity with postoperative complications, length of stay, and mortality in patients with spinal metastases, the authors designed an observational study of 484 cancer patients who received surgical treatment for spinal metastases between 2010 and 2019. Sarcopenia, muscle radiodensity, visceral adiposity, and subcutaneous adiposity were assessed on routinely available 3-month preoperative CT images by using a validated deep learning methodology. The authors used k-means clustering analysis to identify patients with similar body composition characteristics. Regression models were used to examine the associations of sarcopenia, frailty, and clusters with the outcomes of interest. RESULTS Of 484 patients enrolled, 303 had evaluable CT data on muscle and adiposity (mean age 62.00 ± 11.91 years; 57.8% male). The authors identified 2 clusters with significantly different body composition characteristics and mortality risks after spine metastases surgery. Patients in cluster 2 (high-risk cluster) had lower muscle mass index (mean ± SD 41.16 ± 7.99 vs 50.13 ± 10.45 cm2/m2), lower subcutaneous fat area (147.62 ± 57.80 vs 289.83 ± 109.31 cm2), lower visceral fat area (82.28 ± 48.96 vs 239.26 ± 98.40 cm2), higher muscle radiodensity (35.67 ± 9.94 vs 31.13 ± 9.07 Hounsfield units [HU]), and significantly higher risk of 1-year mortality (adjusted HR 1.45, 95% CI 1.05-2.01, p = 0.02) than individuals in cluster 1 (low-risk cluster). Decreased muscle mass, muscle radiodensity, and adiposity were not associated with a higher rate of complications after surgery. Prolonged length of stay (> 7 days) was associated with low muscle radiodensity (mean 30.87 vs 35.23 HU, 95% CI 1.98-6.73, p < 0.001). CONCLUSIONS Body composition analysis shows promise for better risk stratification of patients with spinal metastases under consideration for surgery. Those with lower muscle mass and subcutaneous and visceral adiposity are at greater risk for inferior outcomes.
Collapse
Affiliation(s)
- Elie Massaad
- 1Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Christopher P Bridge
- 2Massachusetts General Hospital and Brigham and Women's Hospital Center for Clinical Data Science, Harvard Medical School, Boston
- 4Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston
| | - Ali Kiapour
- 1Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Mitchell S Fourman
- 3Department of Orthopedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Julia B Duvall
- 1Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Ian D Connolly
- 1Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Muhamed Hadzipasic
- 1Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Ganesh M Shankar
- 1Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Katherine P Andriole
- 2Massachusetts General Hospital and Brigham and Women's Hospital Center for Clinical Data Science, Harvard Medical School, Boston
- 4Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston
| | - Michael Rosenthal
- 4Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston
- 5Department of Radiology, Dana Farber Cancer Institute, Boston
| | - Andrew J Schoenfeld
- 6Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and
| | - Mark H Bilsky
- 7Department of Neurological Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - John H Shin
- 1Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston
| |
Collapse
|
6
|
Hussain I, Goldberg JL, Carnevale JA, Hanz SZ, Reiner AS, Schmitt A, Higginson DS, Yamada Y, Laufer I, Bilsky MH, Barzilai O. Hybrid Therapy (Surgery and Radiosurgery) for the Treatment of Renal Cell Carcinoma Spinal Metastases. Neurosurgery 2022; 90:199-206. [PMID: 35023875 PMCID: PMC9508965 DOI: 10.1227/neu.0000000000001780] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Accepted: 09/01/2021] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND The management of spinal metastatic renal cell carcinoma (mRCC) is controversial regarding extent of resection and radiation dosing. OBJECTIVE To determine outcomes in patients treated with hybrid therapy (separation surgery plus adjuvant stereotactic body radiation therapy [SBRT]) for mRCC. METHODS A retrospective study of a prospectively collected cohort of patients undergoing hybrid therapy for mRCC between 2003 and 2017 was performed. SBRT was delivered as high-dose single-fraction, high-dose hypofractionated, or low-dose hypofractionated. Extent of disease, clinical and operative outcomes, and complications data were collected, and associations with overall survival (OS) and progression-free survival were determined. RESULTS Ninety patients with mRCC with high-grade epidural spinal cord compression (ESCC grades 2 and 3) were treated. Metastases were widespread, oligometastatic, and solitary in 56%, 33%, and 11% of patients, respectively. SBRT delivered was high-dose single-fraction, high-dose hypofractionated, and low-dose hypofractionated in 24%, 56%, and 20% of patients, respectively. The 1-yr cumulative incidence of major complications was 3.4% (95% confidence interval [CI]: 0.0%-7.2%). The median follow-up was 14.2 mo for the entire cohort and 38.3 mo for survivors. The 1-yr cumulative incidence of progression was 4.6% (95% CI: 0.2%-9.0%), which translates to a local control rate of 95.4% (95% CI: 91.0%-99.8%) 1 yr after surgery. The median OS for the cohort was 14.8 mo. CONCLUSION These data support the use of hybrid therapy as a safe and effective strategy for the treatment of renal cell spine metastases.
Collapse
Affiliation(s)
- Ibrahim Hussain
- Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA;
- Department of Neurological Surgery, Weill Cornell Medical College, New York, New York, USA;
| | - Jacob L. Goldberg
- Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA;
- Department of Neurological Surgery, Weill Cornell Medical College, New York, New York, USA;
| | - Joseph A. Carnevale
- Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA;
- Department of Neurological Surgery, Weill Cornell Medical College, New York, New York, USA;
| | - Samuel Z. Hanz
- Department of Neurological Surgery, Weill Cornell Medical College, New York, New York, USA;
| | - Anne S. Reiner
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA;
| | - Adam Schmitt
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Daniel S. Higginson
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Yoshiya Yamada
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Ilya Laufer
- Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA;
- Department of Neurological Surgery, Weill Cornell Medical College, New York, New York, USA;
| | - Mark H. Bilsky
- Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA;
- Department of Neurological Surgery, Weill Cornell Medical College, New York, New York, USA;
| | - Ori Barzilai
- Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA;
| |
Collapse
|
7
|
Massaad E, Duvall JB, Shankar GM, Shin JH. Commentary: Hybrid Therapy (Surgery and Radiosurgery) for the Treatment of Renal Cell Carcinoma Spinal Metastases. Neurosurgery 2022; 90:e35-e36. [PMID: 34995270 DOI: 10.1227/neu.0000000000001803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2021] [Accepted: 10/17/2021] [Indexed: 11/19/2022] Open
Affiliation(s)
- Elie Massaad
- Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | | | | | | |
Collapse
|
8
|
Massaad E, Saylor PJ, Hadzipasic M, Kiapour A, Oh K, Schwab JH, Schoenfeld AJ, Shankar GM, Shin JH. The effectiveness of systemic therapies after surgery for metastatic renal cell carcinoma to the spine: a propensity analysis controlling for sarcopenia, frailty, and nutrition. J Neurosurg Spine 2021; 35:356-365. [PMID: 34171829 DOI: 10.3171/2020.12.spine201896] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Accepted: 12/09/2020] [Indexed: 11/06/2022]
Abstract
OBJECTIVE The effectiveness of starting systemic therapies after surgery for spinal metastases from renal cell carcinoma (RCC) has not been evaluated in randomized controlled trials. Agents that target tyrosine kinases, mammalian target of rapamycin signaling, and immune checkpoints are now commonly used. Variables like sarcopenia, nutritional status, and frailty may impact recovery from spine surgery and are considered when evaluating a patient's candidacy for such treatments. A better understanding of the significance of these variables may help improve patient selection for available treatment options after surgery. The authors used comparative effectiveness methods to study the treatment effect of postoperative systemic therapies (PSTs) on survival. METHODS Univariable and multivariable Cox regression analyses were performed to determine factors associated with overall survival (OS) in a retrospective cohort of adult patients who underwent spine surgery for metastatic RCC between 2010 and 2019. Propensity score-matched (PSM) analysis and inverse probability weighting (IPW) were performed to determine the treatment effect of PST on OS. To address confounding and minimize bias in estimations, PSM and IPW were adjusted for covariates, including age, sex, frailty, sarcopenia, nutrition, visceral metastases, International Metastatic RCC Database Consortium (IMDC) risk score, and performance status. RESULTS In total, 88 patients (73.9% male; median age 62 years, range 29-84 years) were identified; 49 patients (55.7%) had an intermediate IMDC risk, and 29 (33.0%) had a poor IMDC risk. The median follow-up was 17 months (range 1-104 months) during which 57 patients (64.7%) died. Poor IMDC risk (HR 3.2 [95% CI 1.08-9.3]), baseline performance status (Eastern Cooperative Oncology Group score 3 or 4; HR 2.7 [95% CI 1.5-4.7]), and nutrition (prognostic nutritional index [PNI] first tertile, PNI < 40.74; HR 2.69 [95% CI 1.42-5.1]) were associated with worse OS. Sarcopenia and frailty were not significantly associated with poor survival. PST was associated with prolonged OS, demonstrated by similar effects from multivariable Cox analysis (HR 0.55 [95% CI 0.30-1.00]), PSM (HR 0.53 [95% CI 0.29-0.93]), IPW (HR 0.47 [95% CI 0.24-0.94]), and comparable confidence intervals. The median survival for those receiving PST was 28 (95% CI 19-43) months versus 12 (95% CI 4-37) months for those who only had surgery (log-rank p = 0.027). CONCLUSIONS This comparative analysis demonstrated that PST is associated with improved survival in specific cohorts with metastatic spinal RCC after adjusting for frailty, sarcopenia, and malnutrition. The marked differences in survival should be taken into consideration when planning for surgery.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Andrew J Schoenfeld
- 5Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | | | | |
Collapse
|
9
|
Hadgaonkar S, Zawar A, Sanghavi S, Kothari A, Sancheti P, Shyam A. Spinal metastases from renal cell carcinoma: Case note with an overview. INTERDISCIPLINARY NEUROSURGERY 2021. [DOI: 10.1016/j.inat.2020.100994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
10
|
Chaker AN, Bhimani AD, Mehta AI. Commentary: Survival Trends After Surgery for Spinal Metastatic Tumors: 20-Year Cancer Center Experience. Neurosurgery 2021; 88:E271-E272. [PMID: 33428756 DOI: 10.1093/neuros/nyaa509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Accepted: 09/26/2020] [Indexed: 11/12/2022] Open
Affiliation(s)
- Anisse N Chaker
- Department of Neurosurgery, University of Illinois at Chicago, Chicago, Illinois
| | - Abhiraj D Bhimani
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Ankit I Mehta
- Department of Neurosurgery, University of Illinois at Chicago, Chicago, Illinois
| |
Collapse
|
11
|
Schoenfeld AJ. Randomized controlled trials and high-intensity spine surgery. Spine J 2020; 20:1725-1727. [PMID: 32311463 PMCID: PMC7541491 DOI: 10.1016/j.spinee.2020.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Accepted: 04/07/2020] [Indexed: 02/03/2023]
|